These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 35226081)
1. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial. Yu J; Gao Y; Chen L; Wu D; Shen Q; Zhao Z; Liu W; Yang H; Zhang Q; Wang X; Hu P; Zheng Z; Wang X; Liu H; Xu Z; Yan Z; Wu Y; Jin M; Zhang Q; Liu X; Zhu K; Shou C JAMA Netw Open; 2022 Feb; 5(2):e220426. PubMed ID: 35226081 [TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358 [TBL] [Abstract][Full Text] [Related]
3. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD; Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686 [TBL] [Abstract][Full Text] [Related]
4. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J; Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Sah BK; Zhang B; Zhang H; Li J; Yuan F; Ma T; Shi M; Xu W; Zhu Z; Liu W; Yan C; Li C; Liu B; Yan M; Zhu Z Nat Commun; 2020 Nov; 11(1):6093. PubMed ID: 33257672 [TBL] [Abstract][Full Text] [Related]
6. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157 [TBL] [Abstract][Full Text] [Related]
7. POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial. Su L; Zhao S; Yin Y; Huang F; Zhu J; Chen L; ; Lin R Front Med (Lausanne); 2022; 9():861777. PubMed ID: 35983099 [TBL] [Abstract][Full Text] [Related]
8. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133 [TBL] [Abstract][Full Text] [Related]
9. Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial. Wang X; Lu C; Wei B; Li S; Li Z; Xue Y; Ye Y; Zhang Z; Sun Y; Liang H; Li K; Zhu L; Zheng Z; Zhou Y; He Y; Li F; Wang X; Liang P; Huang H; Li G; Shen X; Ji J; Tang Y; Xu Z; Chen L; J Hematol Oncol; 2024 Apr; 17(1):17. PubMed ID: 38589926 [TBL] [Abstract][Full Text] [Related]
10. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. He M; Li Q; Zou R; Shen J; Fang W; Tan G; Zhou Y; Wu X; Xu L; Wei W; Le Y; Zhou Z; Zhao M; Guo Y; Guo R; Chen M; Shi M JAMA Oncol; 2019 Jul; 5(7):953-960. PubMed ID: 31070690 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. Katz MHG; Shi Q; Meyers J; Herman JM; Chuong M; Wolpin BM; Ahmad S; Marsh R; Schwartz L; Behr S; Frankel WL; Collisson E; Leenstra J; Williams TM; Vaccaro G; Venook A; Meyerhardt JA; O'Reilly EM JAMA Oncol; 2022 Sep; 8(9):1263-1270. PubMed ID: 35834226 [TBL] [Abstract][Full Text] [Related]
13. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial. Jiang Z; Xie Y; Zhang W; Du C; Zhong Y; Zhu Y; Jiang L; Dou L; Shao K; Sun Y; Xue Q; Tian Y; Gao S; Zhao D; Zhou A Gastric Cancer; 2024 May; 27(3):571-579. PubMed ID: 38457083 [TBL] [Abstract][Full Text] [Related]
14. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection]. Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920 [No Abstract] [Full Text] [Related]
15. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204. Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352 [TBL] [Abstract][Full Text] [Related]
16. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial. Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial. Lin JX; Xu YC; Lin W; Xue FQ; Ye JX; Zang WD; Cai LS; You J; Xu JH; Cai JC; Tang YH; Xie JW; Li P; Zheng CH; Huang CM JAMA Netw Open; 2021 Jul; 4(7):e2116240. PubMed ID: 34241629 [TBL] [Abstract][Full Text] [Related]
18. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919 [TBL] [Abstract][Full Text] [Related]
19. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258 [TBL] [Abstract][Full Text] [Related]
20. Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. Pietrantonio F; Morano F; Corallo S; Miceli R; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Bergamo F; Sartore-Bianchi A; Tampellini M; Racca P; Clavarezza M; Berenato R; Caporale M; Antista M; Niger M; Smiroldo V; Murialdo R; Zaniboni A; Adamo V; Tomasello G; Giordano M; Petrelli F; Longarini R; Cinieri S; Falcone A; Zagonel V; Di Bartolomeo M; de Braud F JAMA Oncol; 2019 Sep; 5(9):1268-1275. PubMed ID: 31268481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]